PharmOncology

Ming-Hei Tai
  • 5.0 (3)
  • Medicine
  • Updated Weekly

A podcast about pharmacy and oncology

Episodes

  1. Jun 3

    Thoughts on RASolute 302 (for 20 minutes)

    RASolute 302:https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

    21 min

  2. May 27

    ADC Sequencing and the "Sandwich" method

    What we do and do not understand about antibody drug conjugate sequencing. Journal of Thoracic Oncology: https://www.jto.org/article/S1556-0864(26)00007-9/fulltextPost mortem sacituzumab govitecan study:https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/

    9 min

  3. May 20

    Is HRR really a biomarker in prostate cancer?

    Why HRR gene mutations are not the perfect biomarker. PROpel trial: thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-0/fulltext TALAPRO-2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract TRITON-3 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2214676

    8 min

  4. May 15

    Interpreting prospective ctDNA trials

    Some thoughts on how to interpret ctDNA trials that look to validate it as a predictive biomarker

    15 min

  5. May 6

    Why we should look at continuing CD38 antibodies after progression

    There is an explosion of trials in the CD38 antibody space (daratumumab, isatuximab) in multiple myeloma. This episode goes over one key unanswered question which many of the trials are not attempting to answer.

    10 min
  • 5 Episodes

Ratings & Reviews

5
out of 5
3 Ratings

About

A podcast about pharmacy and oncology

Information

  • Creator
    Ming-Hei Tai
  • Years Active
    2K
  • Episodes
    5
  • Rating
    Clean
  • Copyright
    © Ming-Hei Tai
  • Show Website
    PharmOncology

You Might Also Like